Ensign Peak Advisors
CPRX

Ensign Peak Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Ensign Peak Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$177K Hold
7,160
– – ﹤0.01% 1363
2025
Q4 		$167K Sell
7,160
-13,850
-66% -$309K ﹤0.01% 1392
2025
Q3 		$414K Sell
21,010
-27,150
-56% -$558K ﹤0.01% 1470
2025
Q2 		$1.05M Hold
48,160
– – ﹤0.01% 1223
2025
Q1 		$1.17M Hold
48,160
– – ﹤0.01% 1167
2024
Q4 		$1.01M Hold
48,160
– – ﹤0.01% 1314
2024
Q3 		$957K Hold
48,160
– – ﹤0.01% 1345
2024
Q2 		$746K Hold
48,160
– – ﹤0.01% 1458
2024
Q1 		$768K Sell
48,160
-2,430
-5% -$36.6K ﹤0.01% 1484
2023
Q4 		$850K Hold
50,590
– – ﹤0.01% 1472
2023
Q3 		$591K Hold
50,590
– – ﹤0.01% 1540
2023
Q2 		$680K Hold
50,590
– – ﹤0.01% 1520
2023
Q1 		$839K Hold
50,590
– – ﹤0.01% 1391
2022
Q4 		$941K Buy
50,590
+25,350
+100% +$390K ﹤0.01% 1211
2022
Q3 		$324K Buy
25,240
+23,820
+1,677% +$282K ﹤0.01% 1672
2022
Q2 		$10K Buy
+1,420
New +$10.4K ﹤0.01% 2144

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Ensign Peak Advisors's CPRX Position: Q1 2026 in Review

Ensign Peak Advisors held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 7,160 shares worth $177K. The position accounts for ﹤0.01% of the portfolio, ranked #1363.

Ensign Peak Advisors first reported a position in CPRX in Q2 2022 and has held it in 16 quarters since. The position peaked at $1.17M in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Ensign Peak Advisors held 7,160 shares of Catalyst Pharmaceutical worth $177K as of Q1 2026.
  • Ensign Peak Advisors left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q1 2026, its #1363 holding.
  • Ensign Peak Advisors first reported a position in Catalyst Pharmaceutical in Q2 2022 and has held it in 16 quarters since.
  • Ensign Peak Advisors's Catalyst Pharmaceutical position peaked at $1.17M in Q1 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.